Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 2.4 EX-2.4
- 5.1 EX-5.1
- 8.1 EX-8.1
- 8.2 EX-8.2
- 10.16 EX-10.16
- 10.17 EX-10.17
- 10.18 EX-10.18
- 10.19 EX-10.19
- 10.20 EX-10.20
- 10.21 EX-10.21
- 10.22 EX-10.22
- 10.23 EX-10.23
- 10.24 EX-10.24
- 10.25 EX-10.25
- 10.26 EX-10.26
- 10.27 EX-10.27
- 10.28 EX-10.28
- 10.29 EX-10.29
- 10.30 EX-10.30
- 10.31 EX-10.31
- 10.32 EX-10.32
- 10.33 EX-10.33
- 10.34 EX-10.34
- 10.35 EX-10.35
- 23.1 EX-23.1
- 23.2 EX-23.2
- 99.1 EX-99.1
- 99.4 EX-99.4
- 99.5 EX-99.5
- 99.6 EX-99.6
- 99.7 EX-99.7
- 99.8 EX-99.8
- 99.9 EX-99.9
- Download Excel data file
- View Excel data file
ACER similar filings
Filing view
External links
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to use in this Registration Statement on FormS-4 of Opexa Therapeutics, Inc. of our report dated March 22, 2017, except for Note 11, as to which the date is July 19, 2017, relating to the consolidated financial statements of Acer Therapeutics Inc., which report expresses an unqualified opinion and includes an explanatory paragraph relating to Acer Therapeutics Inc.’s ability to continue as a going concern, appearing in the Prospectus, which is part of this Registration Statement.
We also consent to the reference to our firm under the caption “Experts” in such Prospectus.
/s/ Wolf & Company, P.C.
Wolf & Company, P.C.
Boston, Massachusetts
July 19, 2017